Table 1 Patient clinical characteristics.
|  | N = 114 |
|---|---|
Age, years, median (range) | 70 (36–86) |
Gender, male/female | 60.5%/39.5% |
Median baseline eGFR (ml/min/1.73 m2) (range) | 78.42 (22.2–129) |
Median baseline proteinuria (range) (g/24 h) | 0.249 (0.034–8.1) |
Comorbidities | |
 Hypertension | 49 (43%) |
 Diabetes mellitus | 23 (20%) |
 Peripheral angiopathy | 21 (18%) |
 Coronary heart disease | 7 (6%) |
MM immunoglobulin type | |
 κLC | 70 (614%) |
 λLC | 39 (34.2%) |
 Non-secretory | 5 (4.4%) |
Previous HDM/ASCT | 53 (47%) |
Median number of previous treatments (range) | 2 (1–7) |
 Bortezomib | 78% |
 ImiD | 73% |
 Anthracycline | 27% |
 ASCT | 46.5% |
Carfilzomib dose (mg/m2) | |
 20/27 | 30% |
 20/36 | 11% |
 20/56 | 59% |
Carfilzomib-dexamethasone (Kd) | 75% |
Kd+ Lenalidomide (KRd) | 14% |
Other CFz combinations | 11% |
